1[3]Maser RE,Mitchell BD,Vinik AI,et al.The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes:a meta-analysis[J].Diabetes Care,2003,26:895-1901.
2[4]Cohen JA,Estacio RO,Lundgren et al.Diabetic autonomic neuropathy is associated with an increased incidence of strokes[J].Auton Neurosci,2003,108(1-2):73-8.
4[6]Whitsel EA,Boyko EI,Siscovick DS,et al.Reassessing the role of QTc in the diagnosis of autonomic failure among patients with diabetes:a mete-analysis[J].Diabetes Care,2000,23:241-247.
5[7]Pittasch D,Lobmann R,Behrens-Baumann W,et al.Pupil signs of sympathetic autonomic neuropathy in patients with type 1 diabetes[J].Diabetes Care,2002,25:1545-1550.
6[8]The Diabetes Control and Complication Trial Research Group:The effect of intensive treatment of diabetes in the development and progression of long-term complications in insulin-dependent diabetes mellitus[J].N Engl J Med,1993,329:977-986.
7[9]Greene DA,Arezzo JC,Brown MB,et al.Effect of aldose reductase inhibition on nerve condition and morphometry in diabetic neuropathy[J].Zenarestat Study Group.Neurology,1999,53:580-591.
9[11]Ziegler D,Hanefeld M,Ruhnau KJ,et al.Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid:a 7-month multicenter randomized controlled trial(ALADIN Ⅲ STUDY),ALADIN Ⅲ study group,alpha-lipoic acid in diabetic neuropathy[J].Diabetes Care,1999,22:1296-1301.
10[12]Apfel SC,Kessler JA,Adornato BT et al.Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy[J].NGF study group.Neurology,1998,51:695-702.
